Evofem Biosciences, Inc. (EVFM): Nasdaq/NYSE listing notice — Evofem receives OTCQB delisting notice for trading below $0.01 for 30 days; 90-day cure period until April 6, 2025

Evofem Biosciences, Inc.

Received OTC notice on Jan 6, 2025: closing bid price below $0.01 for 30 consecutive days violates Minimum Bid Price Requirement.
Has 90-day compliance period until April 6, 2025 to regain compliance by having bid price >= $0.01 for 10 consecutive trading days.
Failure to regain compliance by April 6, 2025 will result in removal of common stock from OTCQB.
Company says it will monitor bid price and consider available options to resolve deficiency.

item 3.01

Key facts

Extracted from this filing and checked against the source text.

Listing & Compliance Notices SEC 8-K Item 3.01 confidence 0.9

Evofem Biosciences, Inc. received a otc deficiency notice notice regarding minimum bid price.

Exchange: otc
Notice: deficiency notice
Deficiency: minimum bid price

Exact text from the filing

January 6, 2025, Evofem Biosciences, Inc. (the “Company”) received a written notice (the “OTC Notice”) from the OTC Markets Group (“OTC”) notifying the Company that, because the closing bid price for the Company’s common

View on SEC.gov

Listing & Compliance Notices SEC 8-K Item 3.01 confidence 0.9

Evofem Biosciences, Inc. received a otc deficiency notice notice regarding minimum bid price.

Exchange: otc
Notice: deficiency notice
Deficiency: minimum bid price

Exact text from the filing

January 6, 2025, Evofem Biosciences, Inc. (the “Company”) received a written notice (the “OTC Notice”) from the OTC Markets Group (“OTC”) notifying the Company that, because the closing bid price for the Company’s common stock was below $0.01 per share for 30 consecutive calendar days, the Company is not currently in compliance with the minimum bid price requirement for continued listing on OTCQB Venture Market (“OTCQB”), as set forth in the OTCQB listing standards, section 2.3 (the “Minimum Bid Price Requirement”). The OTC Notice has no immediate effect on the listing of the Company’s common

View on SEC.gov

Browse all listing & compliance notices →

Evofem Biosciences, Inc. filing history →

Source: SEC EDGAR

accession 0001493152-25-001682

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.